/CCXI

CCXI Stock - ChemoCentryx, Inc.

Q: What is the analyst price target for CCXI?

Analyst price target information is not currently available for CCXI.

Q: What is CCXI's market cap?

Market capitalization information is not currently available for CCXI.

Healthcare|Biotechnology|NASDAQ

$51.99+0.00%

+$0.00 (+0.00%) • Oct 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+18.6%upside

Target: $61.66

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for CCXI

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2017

FY2018

FY2019

FY2020

FY2021

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.23

52W High$52.00

52W Low$14.95

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2021	FY2020	FY2019	FY2018	FY2017
Revenue	$32.22M	$64.89M	$35.95M	$42.88M	$82.50M
Gross Profit	$31.92M	$64.89M	$35.95M	$42.88M	$82.50M
Gross Margin	99.1%	100.0%	100.0%	100.0%	100.0%
Operating Income	$-134,450,000	$-55,177,000	$-58,303,000	$-40,270,000	$16.49M
Net Income	$-129,060,000	$-55,356,000	$-55,489,000	$-37,966,000	$17.86M
Net Margin	-400.5%	-85.3%	-154.3%	-88.6%	21.6%
EPS	$-1.96	$-0.84	$-0.98	$-0.76	$0.37

Company Overview

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California. As of October 20, 2022, ChemoCentryx, Inc. operates as a subsidiary of Amgen Inc.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

1 Bullish0 Neutral/Bearish

Price Targets

$81

Average Target

↑ 55.8% Upside

Now

$81

Low

$81

Average

$81

High

Based on 1 analyst

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
August 4th 2022	Canaccord Genuity	Resumed	Buy	$81

Earnings History & Surprises

CCXI

Beat Rate

53%

Last 19 quarters

Avg Surprise

+33.7%

EPS vs Estimate

Beats / Misses

10/7

2 met exactly

Latest EPS

$-0.44

Q3 2022

EPS Surprise History

Q4 20

-12.9%

$-0.35vs$-0.31

Q1 21

-30.3%

$-0.43vs$-0.33

Q2 21

-7.5%

$-0.43vs$-0.40

Q3 21

-1.8%

$-0.56vs$-0.55

Q4 21

+28.9%

$-0.32vs$-0.45

Q1 22

0.0%

$-0.58vs$-0.58

Q2 22

-77.4%

$-0.55vs$-0.31

Q3 22

+10.2%

$-0.44vs$-0.49

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2022	Nov 7, 2022	$-0.46	—	—	—
Q3 2022	Aug 8, 2022	$-0.49	$-0.44	+10.2%	✓ BEAT
Q2 2022	May 5, 2022	$-0.31	$-0.55	-77.4%	✗ MISS
Q1 2022	Mar 1, 2022	$-0.58	$-0.58	0.0%	= MET
Q4 2021	Nov 9, 2021	$-0.45	$-0.32	+28.9%	✓ BEAT
Q3 2021	Aug 9, 2021	$-0.55	$-0.56	-1.8%	✗ MISS
Q2 2021	Apr 29, 2021	$-0.40	$-0.43	-7.5%	✗ MISS
Q1 2021	Mar 1, 2021	$-0.33	$-0.43	-30.3%	✗ MISS
Q4 2020	Nov 9, 2020	$-0.31	$-0.35	-12.9%	✗ MISS
Q3 2020	Aug 10, 2020	$-0.34	$0.29	+185.3%	✓ BEAT
Q2 2020	May 11, 2020	$-0.30	$-0.35	-16.7%	✗ MISS
Q1 2020	Mar 10, 2020	$-0.26	$-0.26	0.0%	= MET
Q4 2019	Nov 4, 2019	$-0.28	$-0.22	+21.4%	✓ BEAT
Q3 2019	Aug 5, 2019	$-0.22	$-0.26	-18.2%	✗ MISS
Q2 2019	May 6, 2019	$-0.24	$-0.23	+4.2%	✓ BEAT
Q1 2019	Mar 11, 2019	$-0.27	$-0.21	+22.2%	✓ BEAT
Q4 2018	Nov 8, 2018	$-0.24	$-0.22	+8.3%	✓ BEAT
Q3 2018	Aug 9, 2018	$-0.15	$-0.14	+6.7%	✓ BEAT
Q2 2018	May 9, 2018	$-0.23	$-0.19	+17.4%	✓ BEAT
Q1 2018	Mar 9, 2018	$-0.20	$0.80	+500.0%	✓ BEAT